CC chemokine receptor 5 influences late-stage atherosclerosis
详细信息 查看全文
- 作者：Marlon P. Quinones ; Hernan G. Martinez ; Fabio Jimenez ; Carlos A. Estrada ; Molly Dudley ; Opal Willmon ; Hemant Kulkarni ; Robert L. Reddick ; Gabriel Fern ; es ; William A. Kuziel ; Sunil K. Ahuja ; Seema S.
- 关键词：Atherosclerosis ; Chemokines ; Biomarker ; Inflammation
- 刊名：Atherosclerosis
- 出版年：2007
- 出版时间：November 2007
- 年：2007
- 卷：195
- 期：1
- 页码：e92-e103
- 全文大小：1557 K
文摘
Members of the chemokine system, play a central role in inflammatory processes that underlie the pathogenesis of atherosclerosis and possibly, aortic valve sclerosis. Here we show that genetic inactivation of CC chemokine receptor 5 (CCR5) in the atherosclerosis-prone Apoep>−/− p> mice (Apoep>−/− p>Ccr5p>−/− p>) fed a normal chow or a high-fat diet (HFD) are protected against advanced atherosclerosis as well as age-associated aortic valve thickening (AAAVT)—a murine correlate of aortic valve sclerosis. Notably, human sclerotic valves contained CCR5+ cells. We confirm that Apoep>−/− p>Ccr5p>−/− p> mice does not influence early-atherosclerotic stage. Adoptive transfer studies showed that the atheroprotective effect of CCR5 inactivation resided in the bone marrow compartment, but was not dependent on T-cells. The CCR5-null state was associated with phenotypes postulated to be atheroprotective such as reduced macrophage accumulation in the plaque, and lower circulating levels of IL-6 and MCP-5. The lack of CCR5 expression in Apoep>−/− p> mice was also associated with higher numbers of endothelial progenitor cells (EPCs)—another postulated athero-protective factor. Compared with controls, carriers of a polymorphism in the Ccr5 gene that leads to the lack of CCR5 in the cell surface had an increased mean percentage of EPCs, but this difference did not reach statistical significance. Collectively, these findings underscore a critical role of CCR5 in age-associated cardiovascular diseases, and highlight that the effects of the chemokine system can be temporally constrained to distinct stages of these disease processes.